(Total Views: 375)
Posted On: 10/15/2025 4:36:50 PM
Post# of 158088
This sounds promising, Misiu.
"One indication that carries the potential for significant value return is leronlimab in mTNBC, the most aggressive form of breast cancer, with 5-year survival rates around 15%. Based on the positive data presented at ESMO, we will shortly submit a follow-up Phase II proof of concept (POC) protocol for PD-L1-negative patients with mTNBC. These patients, currently ineligible for ICI therapy, will receive leronlimab plus standard chemotherapy, followed by a regimen of leronlimab with an ICI. We look forward to sharing more details after the FDA review of the protocol and briefing package that provides a complete summary of CytoDyn’s oncology data."
https://www.otcmarkets.com/stock/CYDY/news/Se...?id=494221
And then there's this.
"And recently, we have collated all of our oncology data into a briefing book so that the folks at FDA can now understand what CytoDyn is trying to do. And as a result, it's opening options to us about how we can even further improve our CRC study. So I'm excited about that as well."
https://www.reddit.com/r/Livimmune/comments/1..._how_ccr5/
"One indication that carries the potential for significant value return is leronlimab in mTNBC, the most aggressive form of breast cancer, with 5-year survival rates around 15%. Based on the positive data presented at ESMO, we will shortly submit a follow-up Phase II proof of concept (POC) protocol for PD-L1-negative patients with mTNBC. These patients, currently ineligible for ICI therapy, will receive leronlimab plus standard chemotherapy, followed by a regimen of leronlimab with an ICI. We look forward to sharing more details after the FDA review of the protocol and briefing package that provides a complete summary of CytoDyn’s oncology data."
https://www.otcmarkets.com/stock/CYDY/news/Se...?id=494221
And then there's this.
"And recently, we have collated all of our oncology data into a briefing book so that the folks at FDA can now understand what CytoDyn is trying to do. And as a result, it's opening options to us about how we can even further improve our CRC study. So I'm excited about that as well."
https://www.reddit.com/r/Livimmune/comments/1..._how_ccr5/
(14)
(0)
